Viral Infectivity of Asymptomatic or Mild Symptomatic without Risk Factors COVID-19 Case-patients at 7 and 10 Days after Diagnosis

Authors

  • Somchai Thanasitthichai, M.D. Institute of Medical Research and Technology Assessment
  • Arunee Thaiyakul, M.P.H. Institute of Medical Research and Technology Assessment
  • Nattaya Sanga, M.Sc. Institute of Medical Research and Technology Assessment
  • Yong Poovorawan, M.D. Department of Pediatrics, Faculty of Medicine, Faculty of Medicine, Chulalongkorn University
  • Suthaluk Kwanjaroensub, M.Sc. Institute of Medical Research and Technology Assessment
  • Patchariya Yingin, B.Sc. Institute of Medical Research and Technology Assessment

Keywords:

Antibody, COVID-19, quarantine, virus culture

Abstract

Background: Asymptomatic and mild symptomatic patients with no risk of severe coronavirus disease (COVID-19) will be quarantine for 10 days as Thai guideline’s recommendation. If the quarantine period can be shortened from 10 to 7 days, we can save many resources. Objective: to assess the rate of SARS-CoV-2 (viral infectivity) in asymptomatic and mild symptomatic COVID-19 patients diagnosed on 7th day and 10th day after diagnosis. Method: This prospective descriptive study performed at the hospitel (Narai Hotel) under the supervision of Lerdsin Hospital from March to December 2021. 88 of subjects were recruited. Nasopharyngeal and throat secretion culture for SARS-CoV-2, subgenomic RNA and clotted blood for IgM and IgG using ELISA were collected. Results: We found 64.4% female, mean age 37.1 ± 12.3 years and BMI 23.1 ± 3.5 kg/m2. Asymptomatic and mild symptomatic subjects were 34.1% and 65.9% respectively. rRT-PCR on 7th day and 10th day showed “detected” result 82.9% (95% CI 75.1, 90.8) and 81.8% (95% CI 73.8, 89.9) respectively whereas, virus culture on 7th day were “not detected” 98.9% (95 CI 96.7, 100) and no virus was found on 10th day.  Subgenomic RNA method showed alpha (B.1.1.7) 53.4%, delta 11.4%, and neither alpha nor delta strains 35.2%. Geometric mean titer (GMT) of anti-spike IgM on day 7 and day 10 were 2.42 (95%CI 1.77, 3.30) and 3.45 (95%CI 2.6, 4.6) respectively (p < .001) while anti-RBD IgG were 209.2 and 520.1, respectively (p < .0001). Moreover, IgM and IgG levels on 7th day, the seropositive rates were 79.6% and 77.3% while on 10th day, were 89.8% and 93.2% respectively. Conclusion: The infection on 7th days and 10th day from diagnostic date by RT-PCR showed a large number of infections, virus culture showed very rarely “detected” report on 7th day and “not detected” on 10th day after diagnosis.

Downloads

Download data is not yet available.

Author Biography

Somchai Thanasitthichai, M.D., Institute of Medical Research and Technology Assessment

Institute of Medical Research and Technology Assessment, Department of Medical Services

References

กรมการแพทย์. แนวทางเวชปฏิบัติการวินิจฉัย ดูแลรักษา และป้องกันการติดเชื้อในโรงพยาบาล กรณีโรคติดเชื้อไวรัสโคโรนา 2019 (COVID-19) ฉบับปรับปรุง วันที่ 28 มกราคม พ.ศ. 2564 สําหรับแพทย์และบุคลากรสาธารณสุข [Internet]. 2021; [cited 3 January 2021]. Available from: http://covid19.dms.go.th/Content/Select_Landding_page?contentId=109.

World Health Organization. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance. [cited 1 December 2020]. Available from https://apps.who.int/iris/bitstream/handle/10665/331329/WHO-COVID-19-laboratory-2020.4-eng.pdf

Center for Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19). [cited 1 December 2020]. Available from https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html

สมาคมโรคติดเชื้อในเด็กแห่งประเทศไทย. คู่มือ COVID สำหรับกุมารแพทย์ [Internet]. 2021; [cited 9 March 2021]. Available from: https://pidst.or.th/A880.html.

Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange SW, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nat Cell Biol 2020;581:465–9.

Li K, Huang B, Wu M, Zhong A, Li L, Cai Y, et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat Commun 2020;11:6044.

di Mauro G, Scavone C, Rafaniello C, Rossi F, Capuano A. SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment. Int Immunopharmacol 2020;84:106519.

Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med 2020;26:1193–5.

Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 2020;25:2000180.

Chirathaworn C, Sripramote M, Chalongviriyalert P, Jirajariyavej S, Kiatpanabhikul P, Saiyarin J, et al. SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts, Thailand, April-June 2020. PLoS One 2020;15:e0236905.

Chansaenroj J, Yorsaeng R, Posuwan N, Puenpa J, Sudhinaraset N, Chirathaworn C, et al. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients. Virol J 2021;18:52.

Immergluck K, Gonzalez MD, Frediani JK, Levy JM, Figueroa J, Wood A, et al. Correlation of SARS-CoV-2 subgenomic RNA with antigen detection in nasal midturbinate swab specimens. Emerg Infect Dis 2021;27(11):2887-91.

Li W, Su YY, Zhi SS, Huang J, Zhuang CL, Bai WZ, et al. Virus shedding dynamics in asymptomatic and mildly symptomatic patients infected with SARS-CoV-2. Clin Microbiol Infect 2020;26:1556.e1-1556.e6.

Xiao K, Yang H, Liu B, Pang X, Du J, Liu M, et al. Antibodies Can Last for More Than 1 Year After SARS-CoV-2 Infection: A Follow-Up Study From Survivors of COVID-19. Front Med (Lausanne) 2021;8:684864.

Xia W, Li M, Wang Y, Kazis LE, Berlo K, Melikechi N, et al. Longitudinal analysis of antibody decay in convalescent COVID-19 patients. Sci Rep 2021;11:16796.

Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol 2020;5:eabe0367.

Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell 2020;183:1024-1042.e21.

Perera RAPM, Tso E, Tsang OTY, Tsang DNC, Fung K, Leung YWY, et al. SARS-CoV-2 Virus Culture and Subgenomic RNA for Respiratory Specimens from Patients with Mild Coronavirus Disease. Emerg Infect Dis 2020;26:2701-4.

World Health Organization. Criteria for releasing COVID-19 patients from isolation. [Internet]. 2020 [cited 2020 Jul 4]. Available from: https://www.who.int/publications/i/item/criteria-for-releasing-covid-19-patients-from-isolation.

Immergluck K, Gonzalez MD, Frediani JK, Levy JM, Figueroa J, Wood A, et al. Correlation of SARS-CoV-2 subgenomic RNA with antigen detection in nasal midturbinate swab specimens. Emerg Infect Dis 2021;27(11):2887-91.

Dagotto G, Mercado NB, Martinez DR, Hou YJ, Nkolola JP, Carnahan RH, et al. Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques. J Virol 2021;95:e02370-20.

Alexandersen S, Chamings A, Bhatta TR. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. Nat Commun 2020;11:6059.

Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples. Clin Infect Dis 2020;71:2663-6.

Published

29-06-2022

How to Cite

1.
Thanasitthichai S, Thaiyakul A, สง่า ณ, Poovorawan Y, Kwanjaroensub S, Yingin P. Viral Infectivity of Asymptomatic or Mild Symptomatic without Risk Factors COVID-19 Case-patients at 7 and 10 Days after Diagnosis. j dept med ser [Internet]. 2022 Jun. 29 [cited 2022 Oct. 5];47(2):13-21. Available from: https://he02.tci-thaijo.org/index.php/JDMS/article/view/256786

Issue

Section

Original Article